{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:54:24Z","timestamp":1789736064042,"version":"4.0.1"},"reference-count":59,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openvirologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOVJ"],"published-print":{"date-parts":[[2018,2,28]]},"abstract":"<jats:sec><jats:title>Introduction:<\/jats:title><jats:p>Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and hepatocellular carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Explanation:<\/jats:title><jats:p>Epidemiological studies have indicated that persistent infection with hepatitis C virus (HCV) is a major risk for the development of hepatocellular carcinoma (HCC), mainly through chronic inflammation, cell deaths, and proliferation. Despite the new direct-acting antiviral drugs (DAA\u2019s) being able to clear the HCV, HCC recurrence rate in these patients is still observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>In this review we highlighted some aspects that could be involved in the onset of HCV-induced HCC such as immune system, viral factors and host genetics factors.<\/jats:p><jats:p>Moreover, we focused on some of the last reports about the effects of DAA\u2019s on the HCV clearance and their potential implications in HCC recurrence.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1874357901812010016","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T09:59:07Z","timestamp":1520330347000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals"],"prefix":"10.2174","volume":"12","author":[{"given":"Ivan","family":"Schietroma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Corano","family":"Scheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pinacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Statzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnolfo","family":"Petruzziello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Vullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.biopha.2016.10.078","volume":"84","author":"Chacko S.","year":"2016","unstructured":"Chacko S, Samanta S. \u201cHepatocellular carcinoma: A life-threatening disease\u201d. Biomed Pharmacother 2016; 84 : 1679-88.","journal-title":"Biomed. Pharmacother."},{"key":"ref2","first-page":"e37","volume":"168","author":"Elia G.","year":"2017","unstructured":"Elia G, Fallahi P. Hepatocellular carcinoma and CXCR3 chemokines: A narrative review. Clin Ter 2017; 168 (1) : e37-41.","journal-title":"Clin. Ter."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/JHC.S61146","volume":"3","author":"Balogh J.","year":"2016","unstructured":"Balogh J, Victor D III, Asham EH, et al. Hepatocellular carcinoma: A review. J Hepatocell Carcinoma 2016; 3 : 41-53.","journal-title":"J Hepatocell Carcinoma"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00011-017-1029-3","volume":"66","author":"Nawaz R.","year":"2017","unstructured":"Nawaz R, Zahid S, Idrees M, et al. HCV-induced regulatory alterations of IL-1\u03b2, IL-6, TNF-\u03b1, and IFN-\u03d2 operative, leading liver en-route to non-alcoholic steatohepatitis. Inflamm Res 2017; 66 (6) : 477-86.","journal-title":"Inflamm. Res."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/0974-777X.52979","volume":"1","author":"de Oliveria Andrade L.J.","year":"2009","unstructured":"de Oliveria Andrade LJ, D\u2019Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Paran\u00e1 R. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis 2009; 1 (1) : 33-7.","journal-title":"J. Glob. Infect. Dis."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","volume":"142","author":"Li G.","year":"2017","unstructured":"Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res 2017; 142 : 83-122.","journal-title":"Antiviral Res."},{"key":"ref7","first-page":"305","volume":"22","author":"Kew M.C.","year":"2013","unstructured":"Kew MC. Aflatoxins as a cause of hepatocellular carcinoma. J Gastrointestin Liver Dis 2013; 22 (3) : 305-10.","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1289\/ehp.0901388","volume":"118","author":"Liu Y.","year":"2010","unstructured":"Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: A risk assessment. Environ Health Perspect 2010; 118 (6) : 818-24.","journal-title":"Environ. Health Perspect."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1128\/JVI.03230-15","volume":"90","author":"Vegna S.","year":"2016","unstructured":"Vegna S, Gregoire D, Moreau M, et al. NOD1 participates in the innate immune response triggered by Hepatitis C virus polymerase. J Virol 2016; 90 (13) : 6022-35.","journal-title":"J. Virol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nm.3253","volume":"19","author":"Horner S.M.","year":"2013","unstructured":"Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013; 19 (7) : 879-88.","journal-title":"Nat. Med."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1750-9378-7-7","volume":"7","author":"Buonaguro L.","year":"2012","unstructured":"Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Innate immunity and hepatitis C virus infection: A microarray\u2019s view. Infect Agent Cancer 2012; 7 (1) : 7.","journal-title":"Infect. Agent. Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4254\/wjh.v8.i3.162","volume":"8","author":"Lopes J.A.","year":"2016","unstructured":"Lopes JA, Borges-Canha M, Pimentel-Nunes P. Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis? World J Hepatol 2016; 8 (3) : 162-82.","journal-title":"World J. Hepatol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/pin.12529","volume":"67","author":"Kinowaki K.","year":"2017","unstructured":"Kinowaki K, Soejima Y, Kumagai A, et al. Clinical and pathological significance of myeloid differentiation factor 88 expression in human hepatocellular carcinoma tissues. Pathol Int 2017; 67 (5) : 256-63.","journal-title":"Pathol. Int."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-12-1245","volume":"19","author":"Liang B.","year":"2013","unstructured":"Liang B, Chen R, Wang T, et al. Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma. Clin Cancer Res 2013; 19 (11) : 2905-16.","journal-title":"Clin. Cancer Res."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e1103","DOI":"10.1038\/cddis.2014.71","volume":"5","author":"Jia R-J.","year":"2014","unstructured":"Jia R-J, Cao L, Zhang L, et al. Enhanced myeloid differentiation factor 88 promotes tumor metastasis via induction of epithelial-mesenchymal transition in human hepatocellular carcinoma. Cell Death Dis 2014; 5 : e1103.","journal-title":"Cell Death Dis."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/sj.bjc.6605558","volume":"102","author":"Wang E.L.","year":"2010","unstructured":"Wang EL, Qian ZR, Nakasono M, et al. High expression of Toll-like receptor 4\/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010; 102 (5) : 908-15.","journal-title":"Br. J. Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"15265","DOI":"10.1007\/s13277-016-5409-z","volume":"37","author":"Wang Y.","year":"2016","unstructured":"Wang Y, Jiang Y, Zhou J, et al. Hepatitis C virus promotes hepatocellular carcinogenesis by targeting TIPE2, a new regulator of DNA damage response. Tumour Biol 2016; 37 (11) : 15265-74.","journal-title":"Tumour Biol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e1006321","DOI":"10.1371\/journal.ppat.1006321","volume":"13","author":"Zhang X.","year":"2017","unstructured":"Zhang X, Zhu C, Wang T, et al. GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation. PLoS Pathog 2017; 13 (4) : e1006321.","journal-title":"PLoS Pathog."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e1154249","DOI":"10.1080\/2162402X.2016.1154249","volume":"5","author":"Cariani E.","year":"2016","unstructured":"Cariani E, Pilli M, Barili V, et al. Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. OncoImmunology 2016; 5 (8) : e1154249.","journal-title":"OncoImmunology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1089\/jir.2010.0078","volume":"30","author":"Donnelly R.P.","year":"2010","unstructured":"Donnelly RP, Kotenko SV. Interferon-lambda: A new addition to an old family. J Interferon Cytokine Res 2010; 30 (8) : 555-64.","journal-title":"J. Interferon Cytokine Res."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"Thomas D.L.","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265) : 798-801.","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"Ge D.","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262) : 399-401.","journal-title":"Nature"},{"key":"ref23","author":"Bruening J","year":"2017","unstructured":"Bruening J, Weigel B, Gerold G. The role of type III interferons in Hepatitis C virus infection and therapy J Immunol Res 2017.","journal-title":"J Immunol Res."},{"key":"ref24","author":"Al-Qahtani A","year":"2015","unstructured":"Al-Qahtani A, Al-Anazi M, Abdo AA, et al. Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J Immunol Res 2015.","journal-title":"J Immunol Res."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"37487","DOI":"10.18632\/oncotarget.9303","volume":"7","author":"De Re V.","year":"2016","unstructured":"De Re V, De Zorzi M, Caggiari L, et al. HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2. Oncotarget 2016; 7 (25) : 37487-97.","journal-title":"Oncotarget"},{"key":"ref26","author":"Al-Anazi MR","year":"2017","unstructured":"Al-Anazi MR, Matou-Nasri S, Abdo AA, et al. Association of toll-like receptor 3 single-nucleotide polymorphisms and hepatitis C virus infection. J Immunol Res 2017.","journal-title":"J Immunol Res."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/ni.2758","volume":"15","author":"McFarland A.P.","year":"2014","unstructured":"McFarland AP, Horner SM, Jarret A, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15 (1) : 72-9.","journal-title":"Nat. Immunol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jhep.2015.06.035","volume":"63","author":"O\u2019Brien T.R.","year":"2015","unstructured":"O\u2019Brien TR, Pfeiffer RM, Paquin A, et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol 2015; 63 (5) : 1103-10.","journal-title":"J. Hepatol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1089\/jir.2016.0042","volume":"36","author":"Ibrahim M.K.","year":"2016","unstructured":"Ibrahim MK, Salama H, Abd El Rahman M, et al. Three gene signature for predicting the development of hepatocellular carcinoma in chronically infected hepatitis C virus patients. J Interferon Cytokine Res 2016; 36 (12) : 698-705.","journal-title":"J. Interferon Cytokine Res."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jhep.2016.07.035","volume":"65","author":"Bukh J.","year":"2016","unstructured":"Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol 2016; 65 (1) (Suppl.) : S2-S21.","journal-title":"J. Hepatol."},{"key":"ref31","unstructured":"Chevaliez S, Pawlotsky J-M. HCV genome and life cycle. hepatitis C viruses: Genomes and molecular biology 2006. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1630\/ [Internet] [cited 2017 May 11]"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4254\/wjh.v4.i12.342","volume":"4","author":"Selimovic D.","year":"2012","unstructured":"Selimovic D, El-Khattouti A, Ghozlan H, Haikel Y, Abdelkader O, Hassan M. Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies. World J Hepatol 2012; 4 (12) : 342-55.","journal-title":"World J. Hepatol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"84575","DOI":"10.18632\/oncotarget.12144","volume":"7","author":"Conti B.","year":"2016","unstructured":"Conti B, Porcu C, Viscomi C, et al. Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation. Oncotarget 2016; 7 (51) : 84575-86.","journal-title":"Oncotarget"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"23306","DOI":"10.18632\/oncotarget.4202","volume":"6","author":"He L.","year":"2015","unstructured":"He L, Tian D-A, Li P-Y, He X-X. Mouse models of liver cancer: Progress and recommendations. Oncotarget 2015; 6 (27) : 23306-22.","journal-title":"Oncotarget"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2174\/138920210791233063","volume":"11","author":"Maass T.","year":"2010","unstructured":"Maass T, Sfakianakis I, Staib F, Krupp M, Galle PR, Teufel A. Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics 2010; 11 (4) : 261-8.","journal-title":"Curr. Genomics"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"7989","DOI":"10.1128\/JVI.00280-11","volume":"85","author":"Kannan R.P.","year":"2011","unstructured":"Kannan RP, Hensley LL, Evers LE, Lemon SM, McGivern DR. Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol 2011; 85 (16) : 7989-8001.","journal-title":"J. Virol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jhep.2009.06.026","volume":"51","author":"Park C-Y.","year":"2009","unstructured":"Park C-Y, Choi S-H, Kang S-M, et al. Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J Hepatol 2009; 51 (5) : 853-64.","journal-title":"J. Hepatol."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Dhayat SA, H\u00fcsing A, Senninger N, et al. Circulating microRNA-200 family as diagnostic marker in hepatocellular carcinoma. PLoS One 2015; 10 (10) :e0140066","DOI":"10.1371\/journal.pone.0140066"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S1470-2045(15)00048-0","volume":"16","author":"Lin X-J.","year":"2015","unstructured":"Lin X-J, Chong Y, Guo Z-W, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: A multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015; 16 (7) : 804-15.","journal-title":"Lancet Oncol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ijc.29544","volume":"137","author":"Wen Y.","year":"2015","unstructured":"Wen Y, Han J, Chen J, et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer 2015; 137 (7) : 1679-90.","journal-title":"Int. J. Cancer"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"Charlton M.","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149 (3) : 649-59.","journal-title":"Gastroenterology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/hep.28446","volume":"63","author":"Poordad F.","year":"2016","unstructured":"Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63 (5) : 1493-505.","journal-title":"Hepatology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/gast.2002.33023","volume":"122","author":"Poynard T.","year":"2002","unstructured":"Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122 (5) : 1303-13.","journal-title":"Gastroenterology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7326\/0003-4819-142-2-200501180-00009","volume":"142","author":"Shiratori Y.","year":"2005","unstructured":"Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142 (2) : 105-14.","journal-title":"Ann. Intern. Med."},{"key":"ref45","unstructured":"Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C Gastroenterology 2011."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","volume":"65","author":"Reig M.","year":"2016","unstructured":"Reig M, Mari\u00f1o Z, Perell\u00f3 C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65 (4) : 719-26.","journal-title":"J. Hepatol."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","volume":"65","author":"Conti F.","year":"2016","unstructured":"Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65 (4) : 727-33.","journal-title":"J. Hepatol."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","volume":"65","year":"2016","unstructured":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016; 65 (4) : 734-40.","journal-title":"J. Hepatol."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2013.03.009","volume":"59","author":"Pompili M.","year":"2013","unstructured":"Pompili M, Saviano A, de Matthaeis N, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma \u22643 cm. Results of a multicenter Italian survey. J Hepatol 2013; 59 (1) : 89-97.","journal-title":"J. Hepatol."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/gutjnl-2015-310033","volume":"66","author":"Serti E.","year":"2017","unstructured":"Serti E, Park H, Keane M, et al. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN\u03b1. Gut 2017; 66 (4) : 724-35.","journal-title":"Gut"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jhep.2016.07.004","volume":"65","author":"Nault J-C.","year":"2016","unstructured":"Nault J-C, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol 2016; 65 (4) : 663-5.","journal-title":"J. Hepatol."},{"key":"ref52","unstructured":"Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, et al. 2016. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5172554\/"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","volume":"8","author":"Zhu A.X.","year":"2011","unstructured":"Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: Possible targets and future directions. Nat Rev Clin Oncol 2011; 8 (5) : 292-301.","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1172\/JCI75938","volume":"124","author":"Meissner E.G.","year":"2014","unstructured":"Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124 (8) : 3352-63.","journal-title":"J. Clin. Invest."},{"key":"ref55","first-page":"684","volume":"154","author":"Gozlan Y.","year":"2015","unstructured":"Gozlan Y, Mendelson E, Ben-Ari Z, Mor O. Resistance of hcv to new direct acting antivirals. Harefuah 2015; 154 (11) : 684-687, 743.","journal-title":"Harefuah"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.3390\/v7122968","volume":"7","author":"Ahmed A.","year":"2015","unstructured":"Ahmed A, Felmlee DJ. Mechanisms of hepatitis c viral resistance to direct acting antivirals. Viruses 2015; 7 (12) : 6716-29.","journal-title":"Viruses"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1099\/0022-1317-81-7-1631","volume":"81","author":"Bartenschlager R.","year":"2000","unstructured":"Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81 (Pt 7) : 1631-48.","journal-title":"J. Gen. Virol."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"Pawlotsky J-M.","year":"2016","unstructured":"Pawlotsky J-M, Hepatitis C. Hepatitis c virus resistance to direct-acting antiviral drugs in\u00a0Interferon-free regimens. Gastroenterology 2016; 151 (1) : 70-86.","journal-title":"Gastroenterology"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/jac\/dkp388","volume":"65","author":"Kieffer T.L.","year":"2010","unstructured":"Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65 (2) : 202-12.","journal-title":"J. Antimicrob. Chemother."}],"container-title":["The Open Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openvirologyjournal.com\/contents\/volumes\/V12\/TOVJ-12-16\/TOVJ-12-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openvirologyjournal.com\/contents\/volumes\/V12\/TOVJ-12-16\/TOVJ-12-16.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openvirologyjournal.com\/contents\/volumes\/V12\/TOVJ-12-16\/TOVJ-12-16.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T08:08:06Z","timestamp":1570867686000},"score":1,"resource":{"primary":{"URL":"https:\/\/openvirologyjournal.com\/VOLUME\/12\/PAGE\/16\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2,28]]}},"alternative-id":["TOVJ-12-16"],"URL":"https:\/\/doi.org\/10.2174\/1874357901812010016","relation":{},"ISSN":["1874-3579"],"issn-type":[{"value":"1874-3579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}